These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

103 related articles for article (PubMed ID: 9238818)

  • 1. [Second line treatments of cancers of the ovary].
    Extra JM; Cottu PH
    Rev Prat; 1997 Jun; 47(11):1217-20. PubMed ID: 9238818
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Extending the platinum-free interval in recurrent ovarian cancer: the role of topotecan in second-line chemotherapy.
    Bookman MA
    Oncologist; 1999; 4(2):87-94. PubMed ID: 10337378
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Recurrent and 2nd line therapy in ovarian carcinoma: an overview of conventional systemic therapy modalities].
    du Bois A; Lück HJ; Meerpohl HG
    Zentralbl Gynakol; 1997; 119(7):299-323. PubMed ID: 9340970
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Medical therapy of advanced malignant epithelial tumours of the ovary.
    Colombo N; Parma G; Bocciolone L; Franchi D; Sideri M; Maggioni A
    Forum (Genova); 2000; 10(4):323-32. PubMed ID: 11535983
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Epithelial ovarian cancer: second and third line chemotherapy (review).
    Latorre A; De Lena M; Catino A; Crucitta E; Sambiasi D; Guida M; Misino A; Lorusso V
    Int J Oncol; 2002 Jul; 21(1):179-86. PubMed ID: 12063566
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Treatment of relapsed aggressive lymphomas: regimens with and without high-dose therapy and stem cell rescue.
    Hagemeister FB
    Cancer Chemother Pharmacol; 2002 May; 49 Suppl 1():S13-20. PubMed ID: 12042984
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Response to salvage treatment in recurrent ovarian cancer treated initially with paclitaxel and platinum-based combination regimens.
    Roland PY; Barnes MN; Niwas S; Robertson MW; Alvarez R; Austin JM; Kilgore LC; Partridge EE
    Gynecol Oncol; 1998 Feb; 68(2):178-82. PubMed ID: 9514799
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Timing isn't everything: an analysis of when to start salvage chemotherapy in ovarian cancer.
    McMeekin DS; Tillmanns T; Chaudry T; Gold M; Johnson G; Walker J; Mannel R
    Gynecol Oncol; 2004 Oct; 95(1):157-64. PubMed ID: 15385126
    [TBL] [Abstract][Full Text] [Related]  

  • 9. High-dose topotecan, melphalan, and cyclophosphamide (TMC) with stem cell support: a new regimen for the treatment of advanced ovarian cancer.
    Donato ML; Gershenson DM; Wharton JT; Ippoliti CM; Aleman AS; Bodurka-Bevers D; Bevers MW; Burke TW; Levenback CF; Wolf JK; Freedman RS; Bast RC; Gajewski JL; Champlin RE
    Gynecol Oncol; 2001 Sep; 82(3):420-6. PubMed ID: 11520135
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Haematological evaluation of weekly therapy with topotecan for the treatment of recurrent ovarian cancer resistant to platinum-based therapy.
    Largillier R; Valenza B; Ferrero JM; Novo C; Creisson A; Lesbats G; Mari V; Hebert C; Chamorey E
    Oncology; 2007; 73(3-4):177-84. PubMed ID: 18418010
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The role of topotecan for extending the platinum-free interval in recurrent ovarian cancer: an in vitro model.
    Horowitz NS; Hua J; Gibb RK; Mutch DG; Herzog TJ
    Gynecol Oncol; 2004 Jul; 94(1):67-73. PubMed ID: 15262121
    [TBL] [Abstract][Full Text] [Related]  

  • 12. High-dose chemotherapy with hematopoietic stem cell support in patients with advanced epithelial ovarian cancer: analysis of 67 patients treated in a single institution.
    Bertucci F; Viens P; Gravis G; Blaise D; Faucher C; Oziel-Taoeb S; Bardou VJ; Jacquemier J; Delpero JR; Maraninchi D
    Anticancer Res; 1999; 19(2B):1455-61. PubMed ID: 10365123
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Whole-body hyperthermia (WBH) in combination with carboplatin in patients with recurrent ovarian cancer - a phase II study.
    Atmaca A; Al-Batran SE; Neumann A; Kolassa Y; Jäger D; Knuth A; Jäger E
    Gynecol Oncol; 2009 Feb; 112(2):384-8. PubMed ID: 19059635
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Advanced ovarian cancer: a clinical update on first-line treatment, recurrent disease, and new agents.
    Ozols RF
    J Natl Compr Canc Netw; 2004 Sep; 2 Suppl 2():S60-73. PubMed ID: 19780247
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Second-line therapy for potentially platinum-sensitive recurrent ovarian cancer: what is optimal treatment?
    Markman M
    Gynecol Oncol; 2001 Apr; 81(1):1-2. PubMed ID: 11277641
    [No Abstract]   [Full Text] [Related]  

  • 16. Topotecan versus treosulfan, an alkylating agent, in patients with epithelial ovarian cancer and relapse within 12 months following 1st-line platinum/paclitaxel chemotherapy. A prospectively randomized phase III trial by the Arbeitsgemeinschaft Gynaekologische Onkologie Ovarian Cancer Study Group (AGO-OVAR).
    Meier W; du Bois A; Reuss A; Kuhn W; Olbricht S; Gropp M; Richter B; Lück HJ; Kimmig R; Pfisterer J
    Gynecol Oncol; 2009 Aug; 114(2):199-205. PubMed ID: 19446314
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy and hematologic toxicity of salvage chemotherapy following stem cell-supported high-dose chemotherapy in women with recurrent ovarian cancer.
    Cook S; Penson R; Duska L; Nikrui N; Goodman A; Fuller A; Seiden M
    Gynecol Oncol; 2000 Apr; 77(1):48-54. PubMed ID: 10739690
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Treatment options in patients with recurrent ovarian cancer.
    Gadducci A; Conte P; Cianci C; Negri S; Genazzani AR
    Anticancer Res; 2001; 21(5):3557-64. PubMed ID: 11848523
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Melphalan for the treatment of patients with recurrent epithelial ovarian cancer.
    Davis-Perry S; Hernandez E; Houck KL; Shank R
    Am J Clin Oncol; 2003 Aug; 26(4):429-33. PubMed ID: 12902900
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Platin-based chemotherapy and salvage surgery in recurrent ovarian cancer following negative second-look laparotomy.
    Landoni F; Pellegrino A; Cormio G; Milani R; Maggioni A; Mangioni C
    Acta Obstet Gynecol Scand; 1998 Feb; 77(2):233-7. PubMed ID: 9512334
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.